Literature DB >> 19190348

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

Ramakrishna Edukulla1, Edukulla Ramakrishna, Norman Woller, Bettina Mundt, Sarah Knocke, Engin Gürlevik, Michael Saborowski, Nisar Malek, Michael P Manns, Thomas Wirth, Florian Kühnel, Stefan Kubicka.   

Abstract

Virotherapy can potentially be used to induce tumor-specific immune responses and to overcome tumor-mediated tolerance mechanisms because apoptotic tumor cells are exposed together with viral danger signals during oncolysis. However, insufficient numbers of dendritic cells (DC) present at the site of oncolysis can limit a tumor-specific immune response and the resulting therapeutic benefit. We investigated MHC class I peptide-specific immune responses against model antigens ovalbumin (OVA) and hemagglutinin (HA) in mouse tumor models that support efficient replication of the oncolytic adenovirus hTert-Ad. Virotherapy resulted in peptide-specific cytotoxic T-cell responses against intracellular tumor antigens. Triggering of DC and T-cell infiltration to the oncolytic tumors by macrophage inflammatory protein 1alpha (MIP-1alpha, CCL3) and Fms-like tyrosine kinase-3 ligand (Flt3L) enhanced both antitumoral and antiviral immune responses. Although immune-mediated clearance of the virus can restrict therapeutic efficacy of virotherapy, MIP-1alpha/FLT3L-augmented hTert-Ad virotherapy inhibited local tumor growth more effectively than virotherapy alone. In agreement with the hypothesis that immune-mediated mechanisms account for improved outcome in MIP-1alpha/FLT3L virotherapy, we observed systemic antitumoral effects by MIP-1alpha/FLT3L virotherapy on uninfected lung metastasis in immunocompetent mice but not in nude mice. Furthermore, MIP-1alpha/FLT3L virotherapy of primary tumors was strongly synergistic with tumor DC vaccination in inhibition of established lung metastasis. Combined viroimmunotherapy resulted in long-term survival of 50% of treated animals. In summary, improvement of cross-presentation of tumor antigens by triggering of DC and T-cell infiltration during virotherapy enhances antitumoral immune response that facilitates an effective viroimmunotherapy of primary tumors and established metastases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190348     DOI: 10.1158/0008-5472.CAN-08-1160

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Authors:  Zineb Belcaid; Martine L M Lamfers; Victor W van Beusechem; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

2.  Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.

Authors:  Nicholas M Molino; Medea Neek; Jo Anne Tucker; Edward L Nelson; Szu-Wen Wang
Journal:  Biomaterials       Date:  2016-02-01       Impact factor: 12.479

3.  Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.

Authors:  C M Hennies; R A Reboulet; Z Garcia; S Nierkens; M C Wolkers; E M Janssen
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

4.  Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice.

Authors:  Norman Woller; Sarah Knocke; Bettina Mundt; Engin Gürlevik; Nina Strüver; Arnold Kloos; Bita Boozari; Peter Schache; Michael P Manns; Nisar P Malek; Tim Sparwasser; Lars Zender; Thomas C Wirth; Stefan Kubicka; Florian Kühnel
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

5.  An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.

Authors:  Vincenzo Cerullo; Iulia Diaconu; Valentina Romano; Mari Hirvinen; Matteo Ugolini; Sophie Escutenaire; Sirkka-Liisa Holm; Anja Kipar; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

6.  Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.

Authors:  Yohei Mineharu; A K M Ghulam Muhammad; Kader Yagiz; Marianela Candolfi; Kurt M Kroeger; Weidong Xiong; Mariana Puntel; Chunyan Liu; Eva Levy; Claudia Lugo; Adrina Kocharian; James P Allison; Michael A Curran; Pedro R Lowenstein; Maria G Castro
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

7.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

Review 8.  Going viral with cancer immunotherapy.

Authors:  Brian D Lichty; Caroline J Breitbach; David F Stojdl; John C Bell
Journal:  Nat Rev Cancer       Date:  2014-07-03       Impact factor: 60.716

9.  Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.

Authors:  T Du; G Shi; Y M Li; J F Zhang; H W Tian; Y Q Wei; H Deng; D C Yu
Journal:  Cancer Gene Ther       Date:  2014-07-18       Impact factor: 5.987

Review 10.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.